Premium
Single‐institution long‐term outcomes for patients receiving nonmyeloablative conditioning hematopoeitic cell transplantation for chronic lymphocytic leukemia and follicular lymphoma
Author(s) -
Mortensen Bo K.,
Petersen Søren L.,
Kornblit Brian,
Andersen Per K.,
Braendstrup Peter,
Andersen Niels S.,
Sengeløv Henrik,
Vindeløv Lars
Publication year - 2012
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2012.01801.x
Subject(s) - chronic lymphocytic leukemia , medicine , follicular lymphoma , lymphoma , transplantation , oncology , leukemia , hematopoietic stem cell transplantation , cohort , gastroenterology , immunology
Non‐myeloablative conditioning hematopoietic cell transplantation ( NMC ‐ HCT ) has improved the treatment of chronic lymphocytic leukemia ( CLL ) and follicular lymphoma ( FL ). In a cohort of 85 patients (45 with CLL and 40 with FL ), we observed 5‐yr overall survival ( OS ) and progression‐free survival ( PFS ) of 53% and 38% in the CLL group and 81% and 76% in the FL group. In the both the CLL group and the FL group, a strong trend toward better OS and PFS was observed among patients in complete remission ( CR ) at HCT . Within the FL group, sixteen patients had at one or more time points in their disease history had transformed FL . In contrast to the poor survival found in patients with transformed FL in previous studies, the 5‐yr OS was almost identical in patients with transformed and non‐transformed FL , 83% and 78%, respectively. In conclusion, our study supports that NMC ‐ HCT is a safe and efficacious treatment that can provide long‐term survival in elderly, heavily pretreated patients with FL and CLL . Especially patients with FL , and also transformed FL , seemed to have a great benefit of NMC ‐ HCT , and CR at the time of HCT was an important prognostic factor.